Teva Pharmaceutical Industries will replace its American Depositary Shares with a direct listing of ordinary shares on the New York Stock Exchange, with trading set to begin September 14. ADS holders will receive a one-for-one exchange as the company aims to broaden its shareholder base and optimize its cost of capital. The move could also open the door for inclusion in major indices, potentially boosting visibility and institutional interest. Teva, which has a market capitalization of $40.71 billion, has seen its stock gain 108% over the past 52 weeks, driven by strong sales of branded drugs like Austedo, Ajovy, and Uzedy. Analysts hold a consensus Strong Buy rating with a price target of $38.73, representing a 9.6% upside from current levels.
Teva Pharma Industries Ltd ADRDirect NYSE listing aims to broaden shareholder base, optimize cost of capital, and potentially boost index inclusion and institutional interest.